Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.59 |
| ▸ | TYMP | P19971 | 1/20 | 0.53 |
| ▸ | NT5E | P21589 | 2/20 | 0.51 |
| ▸ | HINT1 | P49773 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL442294 | 0.92 | POLB (0.71) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL15012843 | 0.91 | POLB (0.70) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL16359949 | 0.91 | POLB (0.70) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL338650 | 0.91 | POLB (0.70) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL15798769 | 0.91 | POLB (0.70) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL25171429 | 0.89 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E | |
| SCHEMBL3744960 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL3148595 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL22054664 | 0.89 | POLB (0.68) | POLBP2RY2P2RY4P2RY6TYMP | |
| SCHEMBL1971161 | 0.89 | POLB (0.82) | POLBP2RY2P2RY4P2RY6NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024113009-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-06-06 | — | — | WO | disclosed |
| US-20150175649-A1 | SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-06-25 | — | — | US | disclosed |
| US-20150167017-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2015085318-A2 | TARGETED ADAPTIVE VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015058069-A1 | COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015051214-A1 | POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR | MODERNA THERAPEUTICS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015048744-A2 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015038892-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-1999020753-A2 | PEPTIDE BOND FORMATION USING NUCLEIC ACID CATALYSTS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0381335-A1 | Antiviral agent and novel nucleoside | TANABE SEIYAKU CO., LTD. (JP) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175649-A1 | SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE | MRPL21, PGLS, CFTR | POLB 961/4885P2RY2 562/4885P2RY4 444/4885 |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | POLB 1698/4885P2RY2 4781/4885P2RY4 4643/4885 |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | CHI3L2, CHI3L1, FGF2 | POLB 1035/4885P2RY2 1547/4885P2RY4 3042/4885 |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC47A1, TMEM205 | POLB 1041/4885P2RY2 688/4885P2RY4 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.